Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Summary

The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1) in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC that is not amenable to surgery and/or radiation.

Timeline

Start

2020-12-01

Primary completion

2023-03-10

Completion

2023-03-10

Outcome

Outcome not reported

Stopped (Business): “Due to the company's development strategy adjustment, Innovent Biologics has decided not to continue this study after consultation with investigators.”

Drugs

Indications